---
layout: post
title: "Pharmacogenomic Data Submissions; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:35:57 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-05561
original_published: 2023-03-20 00:00:00 +0000
significance: 8.00
---

# Pharmacogenomic Data Submissions; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 20, 2023 00:00 UTC
**Document Number:** 2023-05561

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Pharmacogenomic Data Submissions." This draft guidance is intended to facilitate progress in the field of pharmacogenomics and the use of pharmacogenomic data in drug development. The draft guidance is intended to clarify the contexts in which pharmacogenomic study findings and data must be included in submissions related to investigational new drug applications (INDs), new drug applications (NDAs), and biologics license applications (BLAs) based on the FDA's regulations. In addition, this document provides recommendations to sponsors and applicants on the format and content of the pharmacogenomic data submissions.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/20/2023-05561/pharmacogenomic-data-submissions-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-05561

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
